
结论很明确:这个市场不值得进入,已经是强竞争、低容错的赛道。 不是预算不够,而是盈利机会太少;新品牌真实可复制的成功样本几乎只有 ZEBORA,整体更像老品牌和高强度打法在吃市场。
These products have successfully captured market share and are profitable. Their design and features are suggested for your investment, based on market competition, saturation, and demand.
Green indicates better success rate, red indicates poorer success rate. If you are a new brand, focus on the left side; if you are an old brand, focus on the right side.
这不是一个适合新卖家进入的市场。 用户预算500,000 CNY远高于单个新ASIN的起步预算,但市场已经明显偏向高竞争、低容错,资金够不代表能赚到钱。
Alternative solutions may pose a risk to your investment in certain markets.
这个市场不值得进入,结论很明确:不是好机会。 目前只有约29.63%的产品可盈利,新品牌新品盈利率只有20%,而且已出现“价格不宽裕但靠低价+投放硬冲”的特征;对小商家来说,真正能复制的成功案例很少,进入后更像是在高风险竞争里烧钱试错。
结论很直接:这个市场不值得进,尤其不适合小卖家。 新品牌只有 1 个,但整体只有 29.63% 产品赚钱,且新上架产品里只有 20.00% 赚钱;真正能活下来的新品牌案例几乎只有 ZEBORA 的 B0DYHLGJTM,别的要么亏损,要么还没跑出来,说明这不是一个靠普通选品就能稳进的市场。
证据很清楚:这更像“品牌硬实力+差异化”市场,不是低成本切入市场。 赚钱的产品几乎都来自老牌:Ascent 的 B0C792GXBC 月销 200、月利润 $2832.79,利润率 31.35%;Rule 1 Proteins 的 B0CP64J1DQ 月利润 $861.71;Z Natural Foods 的 B07NMV2FF7 月利润 $647.50;BulkSupplements 的 B01MV3Z05C 月利润 $269.52。成功原因也很一致:老 ASIN、品牌力、明确差异化(如 Ascent 的原生乳清+军方标签,B0C792GXBC;ZEBORA 的 B0DYHLGJTM 走 10.58 盎司旅行装、易消化、可烘焙、无人工甜味剂),而失败样本多是“同质化+竞争太挤+利润太薄”,例如 Life Extension 的 B07DBFHTS2、TransformHQ 的 B0D7FNQGYL、Earth Fed Muscle 的 B0G6CY85CS。新产品里甚至出现亏损的 $5.99 产品 B0G6CY85CS,利润率 -2.12%,说明低价并不等于能跑通。按这套市场节奏看,用户预算 500,000 CNY 当然足够覆盖入场,但问题不是钱够不够,而是没有足够强的差异化和品牌打法就会被老品牌压住;如果要做小生意,基本必须靠明显创新、包装/功能差异和强营销,不能按普通铺货逻辑进。
最后建议:不要进;如果硬要进,只能跟老品牌学,不要跟普通新品牌学。 大品牌应重点对标 Ascent 的 B0C792GXBC、Rule 1 Proteins 的 B0CP64J1DQ、Z Natural Foods 的 B07NMV2FF7;小生意唯一可参考的是 ZEBORA 的 B0DYHLGJTM,但它不是低门槛成功,而是靠明确小包装差异和功能卖点撑出来的。
All products profit ratio distribution, including all products. For products with insufficient sales or missing profit ratio data, they will be categorized into other rows. This distribution included products that cannot determine the release date.
This are the profit ratios of all new products. There are products without sufficient sales, no more than 100pcs in 3 months, or no profit ratio data, or just released. Those will be considered as 'other'
Most profitable products ranked by profit value. Only includes products with positive profitability and active sales, regardless of release date.
![]() | B0C792GXBC | Ascent | 2022-02-15 | Yes | $45.18 | 200pcs | $9036.0 | 31.35% | $2832.79 |
![]() | B0CP64J1DQ | Rule 1 Proteins | 2024-07-17 | Yes | $29.27 | 100pcs | $2927.0 | 29.44% | $861.71 |
![]() | B07NMV2FF7 | Z Natural Foods | 2013-03-28 | Yes | $24.99 | 100pcs | $2499.0 | 25.91% | $647.5 |
![]() | B0049RFJUQ | simply tera's | 2012-10-18 | Yes | $30.42 | 50pcs | $1521.0 | 32.99% | $501.78 |
![]() | B08C7CFQTR | Z Natural Foods | 2020-07-02 | Yes | $24.99 | 50pcs | $1249.5 | 25.53% | $319.0 |
![]() | B01MV3Z05C | BulkSupplements | 2013-08-13 | Yes | $18.07 | 50pcs | $903.5 | 29.83% | $269.52 |
![]() | B0FG924FGR | PEScience | 2025-07-01 | Yes | $14.99 | 100pcs | $1499.0 | 14.49% | $217.21 |
![]() | B0DYHLGJTM | ZEBORA | 2025-10-21 | Yes | $17.65 | 50pcs | $882.5 | 21.46% | $189.39 |
Most profitable new products ranked by profit value. Only includes newly released products with positive profitability and active sales.
![]() | B0DYHLGJTM | ZEBORA | 2025-10-21 | Yes | $17.65 | 50pcs | $882.5 | 21.46% | $189.39 |
这个市场不值得进入:新品牌真实可复制的成功太少,头部成功几乎都来自老品牌,且新发布里失败明显多于成功,属于高竞争、高壁垒市场。按现有数据看,它不是适合小商家“试错起盘”的赛道;大品牌即使有预算,也要面对强势老品牌和明显的价格/差异化压力。
证据很直接:整体可判断盈利的样本里,盈利率只有29.63%,而新发布产品的盈利率只有20.00%;按新发布拆开看,80.00%是亏损,新品牌里也只有50.00%能盈利,但这只是ZEBORA这一个新品牌的样本,不能说明小品牌普遍能成。更关键的是,成功几乎被老品牌垄断:Ascent、BulkSupplements、Rule 1 Proteins、PEScience、simply tera's、Z Natural Foods都在盈利样本里出现,而老品牌的新发布是100.00%亏损;这说明新品进入后,老牌优势非常强,新品牌想赢只能靠更明确的差异化和更高投入。ZEBORA是唯一新品牌里跑出来的正例,ASIN B0DYHLGJTM,售价17.65美元,月收入88,250,预算11,176.72美元,利润率21.46%,靠的是小规格旅行装、草饲乳清分离蛋白、易消化、可烘焙这类差异化;但同品牌另一款B0FX4FLNV9直接失败,说明这个方向并不稳。老品牌里,Ascent的B0C792GXBC月收入903,600,售价45.18美元,利润率31.35%,靠品牌力、功能差异和视觉差异取胜;PEScience的B0FG924FGR和Rule 1 Proteins的B0CP64J1DQ也都在盈利样本里,说明大品牌要进入,必须按这些头部老牌的标准去打,预算不能只看11,176.72美元这类前期成本,后续品牌、研发和认证投入会更重。
What is the ratio of profitable products
What is the ratio of different brands owning all profitable new products
What is the ratio of different brands owning all nonprofitable new products
这个市场不值得进入,已经接近价格战区,而且对新品牌极不友好。 近一年新品牌新品成功率只有20%,但真正能跑通的只有ZEBORA的B0DYHLGJTM;与此同时,老品牌新上架全部失败,说明现在不是“谁来都能赢”,而是只有既有品牌力、既有旧链接基础和明确差异化才能活下来。
Y-axis is product counts. X-axis is time period. For each time period, there are 2 column, each column is a released type of a product. Columns are in following orders: New product, New product on old listing
Y-axis is product counts. X-axis is time period. For each time period, there are 2 column, each column is a released type of a product. Columns are in following orders: New product, New product on old listing
Header is the profit ratios and first column is different time period. Each cells includes how many products are relased at the specific timerange and has a corresponding profit ratios. Only profitable and with active sales (more than 100 pcs in 3 months) will be considered. Any products without sufficient sold units in 3 months will be marked as 'other'.
| Time/Profit% | x < -10.0% | -10.0% <= x < 0.0% | 0.0% <= x < 10.0% | 10.0% <= x < 20.0% | 20.0% <= x < 30.0% | 30.0% <= x < 40.0% | x >= 40.0% | other |
|---|---|---|---|---|---|---|---|---|
| 2022 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2023 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2024 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2025 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 2 |
| 2026 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Header is the profit ratios and first column is different time period. Each cells includes how many products are relased at the specific timerange and has a corresponding profit ratios. Only profitable and with active sales (more than 100 pcs in 3 months) will be considered. Any products without sufficient sold units in 3 months will be marked as 'other'.
| Time/Profit% | x < -10.0% | -10.0% <= x < 0.0% | 0.0% <= x < 10.0% | 10.0% <= x < 20.0% | 20.0% <= x < 30.0% | 30.0% <= x < 40.0% | x >= 40.0% | other |
|---|---|---|---|---|---|---|---|---|
| 2025/8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2025/9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| 2025/10 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| 2025/11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2025/12 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2026/1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2026/2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2026/3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| 2026/4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2026/5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2026/6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2026/7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |